LDS/Medical Tests/Platelet Count

Platelet Count

Platelets, or thrombocytes, are produced in bone marrow from cells called megakaryocytes. They are non-DNA containing cell fragments that play a large part in blood coagulation, particularly on the arterial side, and have a 7-10 day life cycle. The production of platelets depends on thrombopoietin that is produced in the liver. When the amount of thrombopoietin increases, more megakaryocytes are produced and platelets are stimulated to break off from the megakaryocytes. Normal blood circulating platelet count is 150,000 to 450,000 platelets per uL but can vary depending on patient status such as pregnancy, infection, or other inflammatory responses. Approximately one-third of platelets are stored in the spleen and eventually are destroyed by the spleen.

Abnormal platelet function can occur in thrombocytopenia (decreased platelet count) or thrombocytosis (increased platelet count). Thrombocytopenia is present in autoimmune disorders such as Idiopathic Thrombocytopenic Purpura (ITP), Drug-Induced thrombocytopenia, Connective tissue diseases, Post-transfusion Purpura (PTP), and Platelet refractoriness due to transfusion. It is also seen in myelophthisic bone marrow disorders such as aplastic anemia, leukemia, or metastatic cancer. A benign reason for thrombocytopenia is Vitamin B12 or folate deficiency. Thrombocytosis, which is less common, can be seen in myeloproliferative syndromes such as Essential Thrombocythemia (ET) and Polycythemia Vera, certain leukemias, myelofibrosis, iron deficiency, severe infection, trauma, or stress. Platelet counts are usually performed by automation initially with a manual count if the automated count exceeds specified limits.

  • Diagnosis of bleeding disorders, purpura, petechiae
  • As an aid in diagnosis of drug-induced thrombocytopenia
  • Diagnosis of idiopathic thrombocytopenic purpura
  • As an aid in diagnosis of disseminated intravascular coagulation (DIC)
  • As an aid in diagnosis of hypercoagulable states and chemotherapeutic management of malignant disease
  • Tested as part of massive transfusion protocol to support replacement component decisions.

Increased in:

  • Myeloproliferative disorders (PV, chronic myeloid leukemia, essential thrombocythemia, myelofibrosis)
  • Acute blood loss
  • Post-splenectomy
  • Pre-eclampsia
  • Reactive thrombocytosis secondary to inflammatory disorders
  • Infection
  • Tissue injury
  • Iron deficiency
  • Malignancies

Decreased in:

  • Decreased production: bone marrow suppression or replacement/infiltration
  • Chemotherapy
  • Drugs
  • Alcohol
  • Infection (e.g., HIV)
  • Congenital marrow failure
  • Increased destruction or excessive pooling: hypersplenism
  • DIC
  • Platelet antibodies
  • Evans syndrome
  • Posttransfusion purpura
  • Neonatal isoimmune thrombocytopenia

150,000 - 450,000/μL

Panic: <50,000/uL

 

 

Impedance Counter, Optical Counter (Flow Cytometry), Manual Hemocytometer Method.

Whole Blood EDTA (Lavender).

Stability

  • Ambient: 48 hours
  • Refrigerated: 1-3 days. 
Complete Blood Count, Reticulated Platelet Count, Thrombopoietin, Anti-Platelet Antibody, Prothrombin time, Activated Partial Thromboplastin Time, Antiphospholipid antibody, Platelet aggregation, DIC Panel, Peripheral Blood smear review.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Blood Rev. 2002;16:73. [PMID: 11914001]
  • Br J Haematol. 2005;131:588. [PMID: 16351634]
  • Curr Opin Hematol. 2005;12:499. [PMID: 16217169]
  • Curr Hematol Rep. 2006;5:55. [PMID: 16537047]
  • Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).
  • George Fritsma KD. Hematology, Clinical Principles and Applications, 3rd Edition. St. Louis: Saunders Elsevier (2007).